Phio Pharmaceuticals Corp. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Phio Pharmaceuticals Corp. on April 20, 2023. The filing serves to amend Exhibit 23.1 (Consent of Independent Registered Public Accounting Firm) included in the Company's Annual Report on Form 10-K for the year ended December 31, 2022, which was originally filed on March 22, 2023.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is an administrative amendment and does not contain new financial data or operational results.
Material Changes
The filing addresses an inadvertent omission in the original Exhibit 23.1, which failed to reference certain of the Company's registration statements on Form S-1. The revised consent supersedes the original. The Company explicitly states that this revision does not change any previously reported financial results of operations or any other portion of the auditor's report dated March 22, 2023.
Guidance, Outlook, and Risks
The filing contains no new guidance, outlook, management commentary, risks, contingencies, or unusual items. The sole purpose is to correct the scope of the auditor's consent regarding specific registration statements.
Key Facts for Investor Verification
- The filing is a corrective amendment to the auditor's consent (Exhibit 23.1) in the 2022 Form 10-K.
- The amendment adds references to certain Form S-1 registration statements that were inadvertently omitted.
- There are no changes to the financial results or the auditor's opinion previously reported.
- The independent registered public accounting firm is BDO USA, LLP.